<DOC>
	<DOCNO>NCT00082082</DOCNO>
	<brief_summary>The objective Phase II trial compare efficacy safety 6 month treatment thymalfasin plus trans arterial chemoembolization ( TACE ) TACE alone adult patient non-surgical hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Trial Thymalfasin Adult Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>Signed write informed consent . Diagnosis HCC : 1 . Presence HCC biopsy ( core biopsy ) , , biopsy strongly contraindicate due safety patientrelated concern , diagnosis HCC determine : 2 . A new hepatic defect image AFP &gt; 1000 ng/ml , 3 . A new hepatic defect ultrasound CT AFP &lt; 1000 ng/ml one follow present : 1 . At least two additional image technique show sign characteristic HCC , 2 . The new hepatic defect double diameter time , 3 . The AFP progressively rise &gt; 200 ng/ml triple mean baseline . HCC must unresectable nontransplantable . Hematocrit &gt; 30 % , platelet count &gt; = 50,000 per microliter , WBC &gt; 2.0 x 109/L , polymorphonuclear white cell count &gt; = 1.0 x 109/L . Adequate renal function demonstrate serum creatinine level &lt; 1.5 mg/dl . If patient woman , use definitive method birth control consultation physician , surgically sterile postmenopausal . Concomitant chronic use drug know hepatotoxic , immunosuppressive drug ( Use oral contraceptive exclude otherwise eligible patient ) . Presence main portal vein thrombosis hepatic artery malformation . HCC amenable treatment surgical resection hepatic transplantation . HIV infection diagnose HIV seropositivity confirm Western blot . Concomitant prior history malignancy HCC within last 10 year , except curatively treat skin cancer surgically cure situ carcinoma cervix . Active infectious process selflimiting nature . TB AIDS examples infectious process selflimiting nature . Pregnancy document urine pregnancy test . Women reproductive potential must agree practice adequate method birth control duration study . Alcohol intravenous drug abuse within previous 1 year . Previous treatment thymalfasin . Patients know hypersensitivity iodine . Simultaneous participation another investigational drug study , participation clinical trial involve investigational drug within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>